Compare Boston Scientific Corporation (BSX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Procter & Gamble Co — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Procter & Gamble Co trades at $146.1 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 5.1× Boston Scientific Corporation's market cap, and Procter & Gamble Co pays a 2.92% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PG | |
|---|---|---|
Market Cap | $66.37B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $167.18 |
52-Week Low | $42.63 | $138.10 |
Enterprise Value | $75.94B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Procter & Gamble (PG) trades at $148.37, up 0.9% on the day, with a neutral technical signal and bullish moving averages. The stock shows stable revenue near $84.3 billion in 2025 and consistent earnings beats, with a net income margin of 19.16%. Recent news highlights its dividend reliability amid market volatility, while analyst consensus leans bullish with a $161.71 price target.
PG offers steady growth and income appeal, supported by strong cash flow and a 69-year dividend growth streak. Risks include premium valuation multiples and soft demand concerns. Upside depends on execution of supply chain efficiencies and sustained margin strength in a competitive consumer staples landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
